Ispecimen Stock EBITDA
| ISPC Stock | USD 4.44 0.14 3.06% |
iSpecimen fundamentals help investors to digest information that contributes to ISpecimen's financial success or failures. It also enables traders to predict the movement of ISpecimen Stock. The fundamental analysis module provides a way to measure ISpecimen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ISpecimen stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -9.1 M | -8.6 M |
ISpecimen | EBITDA |
iSpecimen Company EBITDA Analysis
ISpecimen's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current ISpecimen EBITDA | (9.1 M) |
Most of ISpecimen's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iSpecimen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ISpecimen EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for ISpecimen is extremely important. It helps to project a fair market value of ISpecimen Stock properly, considering its historical fundamentals such as EBITDA. Since ISpecimen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ISpecimen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ISpecimen's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
ISpecimen Ebitda
Ebitda |
|
According to the company disclosure, iSpecimen reported earnings before interest,tax, depreciation and amortization of (9.1 Million). This is 101.04% lower than that of the Biotechnology sector and 102.62% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.23% higher than that of the company.
ISpecimen EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ISpecimen's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ISpecimen could also be used in its relative valuation, which is a method of valuing ISpecimen by comparing valuation metrics of similar companies.ISpecimen is currently under evaluation in ebitda category among its peers.
ISpecimen ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ISpecimen's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ISpecimen's managers, analysts, and investors.Environmental | Governance | Social |
ISpecimen Institutional Holders
Institutional Holdings refers to the ownership stake in ISpecimen that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ISpecimen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ISpecimen's value.| Shares | Northern Trust Corp | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 0.0 | Main Street Financial Solutions, Llc (pa) | 2024-09-30 | 0.0 | Sachetta Llc | 2024-09-30 | 0.0 | Blackrock Inc | 2024-06-30 | 56.5 K | Hrt Financial Llc | 2024-06-30 | 45.9 K | Virtu Financial Llc | 2024-06-30 | 42.1 K | Geode Capital Management, Llc | 2024-06-30 | 38.5 K | Citadel Advisors Llc | 2024-06-30 | 25.5 K |
ISpecimen Fundamentals
| Return On Equity | -1.09 | ||||
| Return On Asset | -0.44 | ||||
| Profit Margin | (0.92) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 3.71 M | ||||
| Shares Outstanding | 962.64 K | ||||
| Shares Owned By Insiders | 14.50 % | ||||
| Shares Owned By Institutions | 4.26 % | ||||
| Number Of Shares Shorted | 41.18 K | ||||
| Price To Earning | 0.78 X | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 0.41 X | ||||
| Revenue | 9.93 M | ||||
| Gross Profit | 5.65 M | ||||
| EBITDA | (9.1 M) | ||||
| Net Income | (11.1 M) | ||||
| Cash And Equivalents | 23.69 M | ||||
| Cash Per Share | 2.67 X | ||||
| Total Debt | 196.24 K | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 13.37 X | ||||
| Book Value Per Share | 5.68 X | ||||
| Cash Flow From Operations | (5.81 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (18.12) X | ||||
| Price To Earnings To Growth | (0.09) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 53 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 4.27 M | ||||
| Total Asset | 15.82 M | ||||
| Retained Earnings | (59.36 M) | ||||
| Working Capital | 2.19 M | ||||
| Net Asset | 15.82 M |
About ISpecimen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iSpecimen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ISpecimen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iSpecimen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:Check out ISpecimen Piotroski F Score and ISpecimen Altman Z Score analysis. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.12) | Revenue Per Share 19.19 | Quarterly Revenue Growth (0.04) | Return On Assets (0.44) | Return On Equity (1.09) |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.